OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Psychopharmacology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	213
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	135
Ketamine: A tale of two enantiomers	124
Pivotal mental states	83
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD	74
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review	71
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin	66
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder	64
Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology	61
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	60
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches	58
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	57
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	48
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial	46
Associations between lifetime classic psychedelic use and markers of physical health	46
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial	46
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review	45
Dose–response relationships of psilocybin-induced subjective experiences in humans	44
Modulation of microglial activation by antidepressants	44
Psychedelics and health behaviour change	42
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	38
Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis	38
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties	38
A narrative synthesis of research with 5-MeO-DMT	35
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults	34

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals	34
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	33
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action	33
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis	32
Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice	31
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies	30
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials	30
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms	30
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?	29
Fifty years on: Serotonin and depression	29
Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings	28
Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches	28
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes	27
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults	27
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial	26
Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca	26
Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials	26
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility	25
Belief changes associated with psychedelic use	25
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis	25
Rodent models for nicotine withdrawal	24
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence	24
A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis	24
Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology	23
Beyond the ‘purple drank’: Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports	23
Cannabidiol modulation of hippocampal glutamate in early psychosis	22
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample	22
A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression	21
Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5/AKT/NF-κB signaling pathway	21
Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019	21
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	21
Investigating the effect of crocin on memory deficits induced by total sleep deprivation (TSD) with respect to the BDNF, TrkB and ERK levels in the hippocampus of male Wistar rats	21
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	20
Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood	20
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking	20
Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice	20
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity	19
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	19
Point-of-care measurement of clozapine concentration using a finger-stick blood sample	18
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	18
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature	18
Cannabis-induced oceanic boundlessness	18
Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review	18
Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension	17
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis	17
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology	17
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	17
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	17
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study	16
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze	16

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption	16
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania	16
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences	16
AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar–Kyoto rats	16
MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinde	15
Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis	15
Pharmacological evidence of a cholinergic contribution to elevated impulsivity and risky decision-making caused by adding win-paired cues to a rat gambling task	15
A unified model of ketamine’s dissociative and psychedelic properties	15
Increasing recreational nitrous oxide use: Should we worry? A narrative review	15
Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction	15
Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder	14
Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study	14
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use	14
Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29)	14
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms	14
Oxytocin-induced facilitation of learning in a probabilistic task is associated with reduced feedback- and error-related negativity potentials	14
Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans	14
The effect of metformin on cognitive function: A systematic review and meta-analysis	14
Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study	13
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	13
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes	13
Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study	13
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review	13
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	13
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	13
The New Zealand drug harms ranking study: A multi-criteria decision analysis	13
Nitric oxide-mediated defensive and antinociceptive responses organised at the anterior hypothalamus of mice are modulated by glutamatergic inputs from area 24b of the cingulate cortex	13
CB₁ receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers	12
Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview	12
Individual and combined effects of cannabidiol and Δ⁹-tetrahydrocannabinol on striato-cortical connectivity in the human brain	12
Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016	12
Postpartum psychosis: A proposed treatment algorithm	12
The effects of reserpine on depression: A systematic review	12
Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age	12
Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data	12
Neuropsychological performance in young adults with cannabis use disorder	11
Psilocybin history, action and reaction: A narrative clinical review	11
Regular cannabis use modulates the impact of HIV on the neural dynamics serving cognitive control	11
Intranasal oxytocin may help maintain romantic bonds by decreasing jealousy evoked by either imagined or real partner infidelity	11
Sex-specific sensitivity to methamphetamine-induced schizophrenia-relevant behaviours in neuregulin 1 type III overexpressing mice	11
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice	11
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	11
Time-dependent association between selective serotonin reuptake inhibitors and hospitalization due to hyponatremia	11
Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data	11
To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A sy	11
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	11
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	11
Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction	11
Examining the role of systemic chronic inflammation in diet and sleep relationship	10
Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study	10
Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials	10
A Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder	10
The antidepressant effect and safety of non-intranasal esketamine: A systematic review	10
Sustained NMDA receptor hypofunction impairs brain-derived neurotropic factor signalling in the PFC, but not in the hippocampus, and disturbs PFC-dependent cognition in mice	10
Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review	10
Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorder	10